PharmaEssentia Corp. Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Burlington MA United States (2003)

Organization Overview

First Clinical Trial
2009
NCT05129644
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

PharmaEssentia | PharmaEssentia Corp. | PharmaEssentia Corporation | PharmaEssentia Corporation (Co-Sponsor for USA) | PharmaEssentia (Co-Sponsor for USA) | PharmaEssentia Japan K.K. | PharmaEssentia USA Corporation

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 1)

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Communicable Diseases (Phase 3)

Hepatitis (Phase 2)

Hepatitis A (Phase 1)

Hepatitis B (Phase 1)

Hepatitis B, Chronic (Phase 1)

Hepatitis C (Phase 3)

Hepatitis C, Chronic (Phase 3)

Hepatitis, Chronic (Phase 1)

Hepatitis D (Phase 1)

Hepatitis D, Chronic (Phase 1)

Infections (Phase 3)

Polycythemia (Phase 3)

Polycythemia Vera (Phase 3)

Thrombocythemia, Essential (Phase 3)

Thrombocytosis (Phase 3)

Virus Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 20
  • # of Trial APIs: 10